ICER Chief Scientific Officer Bradt Brings Pharma Perspective
Pamela Brandt joins health technology assessment group after stints at Aegerion, Astellas and Abbott Labs.
You may also be interested in...
Public statements by Novartis and AveXis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.